These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37947591)

  • 1. Treatment of Naturally Occurring Tendon Disease with Allogeneic Multipotent Mesenchymal Stromal Cells: A Randomized, Controlled, Triple-Blinded Pilot Study in Horses.
    Burk J; Wittenberg-Voges L; Schubert S; Horstmeier C; Brehm W; Geburek F
    Cells; 2023 Oct; 12(21):. PubMed ID: 37947591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of single intralesional treatment of surgically induced equine superficial digital flexor tendon core lesions with adipose-derived mesenchymal stromal cells: a controlled experimental trial.
    Geburek F; Roggel F; van Schie HTM; Beineke A; Estrada R; Weber K; Hellige M; Rohn K; Jagodzinski M; Welke B; Hurschler C; Conrad S; Skutella T; van de Lest C; van Weeren R; Stadler PM
    Stem Cell Res Ther; 2017 Jun; 8(1):129. PubMed ID: 28583184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical follow-up of horses treated with allogeneic equine mesenchymal stem cells derived from umbilical cord blood for different tendon and ligament disorders.
    Van Loon VJ; Scheffer CJ; Genn HJ; Hoogendoorn AC; Greve JW
    Vet Q; 2014; 34(2):92-7. PubMed ID: 25072527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking of autologous adipose tissue-derived mesenchymal stromal cells with in vivo magnetic resonance imaging and histology after intralesional treatment of artificial equine tendon lesions--a pilot study.
    Geburek F; Mundle K; Conrad S; Hellige M; Walliser U; van Schie HT; van Weeren R; Skutella T; Stadler PM
    Stem Cell Res Ther; 2016 Feb; 7():21. PubMed ID: 26830812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a single injection of autologous conditioned serum (ACS) on tendon healing in equine naturally occurring tendinopathies.
    Geburek F; Lietzau M; Beineke A; Rohn K; Stadler PM
    Stem Cell Res Ther; 2015 Jun; 6(1):126. PubMed ID: 26113022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intralesional platelet-rich plasma (PRP) treatment on clinical and ultrasonographic parameters in equine naturally occurring superficial digital flexor tendinopathies - a randomized prospective controlled clinical trial.
    Geburek F; Gaus M; van Schie HT; Rohn K; Stadler PM
    BMC Vet Res; 2016 Sep; 12(1):191. PubMed ID: 27604193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons.
    Schnabel LV; Lynch ME; van der Meulen MC; Yeager AE; Kornatowski MA; Nixon AJ
    J Orthop Res; 2009 Oct; 27(10):1392-8. PubMed ID: 19350658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon.
    Godwin EE; Young NJ; Dudhia J; Beamish IC; Smith RK
    Equine Vet J; 2012 Jan; 44(1):25-32. PubMed ID: 21615465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of autologous bone marrow-derived mesenchymal stem cells in naturally occurring tendinopathy.
    Smith RK; Werling NJ; Dakin SG; Alam R; Goodship AE; Dudhia J
    PLoS One; 2013; 8(9):e75697. PubMed ID: 24086616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of mesenchymal stromal cells versus serum on tendon healing in a controlled experimental trial in an equine model.
    Ahrberg AB; Horstmeier C; Berner D; Brehm W; Gittel C; Hillmann A; Josten C; Rossi G; Schubert S; Winter K; Burk J
    BMC Musculoskelet Disord; 2018 Jul; 19(1):230. PubMed ID: 30021608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cell licensing: enhancing MSC function as a translational approach for the treatment of tendon injury.
    Koch DW; Schnabel LV
    Am J Vet Res; 2023 Sep; 84(10):1-8. PubMed ID: 37669745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of autologous bone marrow and adipose tissue derived mesenchymal stem cells, and platelet rich plasma, for treating surgically induced lesions of the equine superficial digital flexor tendon.
    Romero A; Barrachina L; Ranera B; Remacha AR; Moreno B; de Blas I; Sanz A; Vázquez FJ; Vitoria A; Junquera C; Zaragoza P; Rodellar C
    Vet J; 2017 Jun; 224():76-84. PubMed ID: 28697880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution and persistence of technetium-99 hexamethyl propylene amine oxime-labelled bone marrow-derived mesenchymal stem cells in experimentally induced tendon lesions after intratendinous injection and regional perfusion of the equine distal limb.
    Sole A; Spriet M; Padgett KA; Vaughan B; Galuppo LD; Borjesson DL; Wisner ER; Vidal MA
    Equine Vet J; 2013 Nov; 45(6):726-31. PubMed ID: 23574488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of injected technetium(99m)-labeled mesenchymal stem cells in horses with naturally occurring tendinopathy.
    Becerra P; Valdés Vázquez MA; Dudhia J; Fiske-Jackson AR; Neves F; Hartman NG; Smith RK
    J Orthop Res; 2013 Jul; 31(7):1096-102. PubMed ID: 23508674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the efficacy of amnion-derived compared with bone marrow-derived mesenchymal stromal cells in equine tendon and ligament injuries.
    Lange-Consiglio A; Tassan S; Corradetti B; Meucci A; Perego R; Bizzaro D; Cremonesi F
    Cytotherapy; 2013 Aug; 15(8):1011-20. PubMed ID: 23602577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal Stromal Cells Adapt to Chronic Tendon Disease Environment with an Initial Reduction in Matrix Remodeling.
    Doll CU; Niebert S; Burk J
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of equine chondrogenic-induced mesenchymal stem cells as a treatment for osteoarthritis: A randomised, double-blinded, placebo-controlled proof-of-concept study.
    Broeckx SY; Martens AM; Bertone AL; Van Brantegem L; Duchateau L; Van Hecke L; Dumoulin M; Oosterlinck M; Chiers K; Hussein H; Pille F; Spaas JH
    Equine Vet J; 2019 Nov; 51(6):787-794. PubMed ID: 30815897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equine allogeneic umbilical cord blood derived mesenchymal stromal cells reduce synovial fluid nucleated cell count and induce mild self-limiting inflammation when evaluated in an lipopolysaccharide induced synovitis model.
    Williams LB; Koenig JB; Black B; Gibson TW; Sharif S; Koch TG
    Equine Vet J; 2016 Sep; 48(5):619-25. PubMed ID: 26114736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study.
    Guest DJ; Smith MR; Allen WR
    Equine Vet J; 2008 Mar; 40(2):178-81. PubMed ID: 18267891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: A clinical pilot study.
    Magri C; Schramme M; Febre M; Cauvin E; Labadie F; Saulnier N; François I; Lechartier A; Aebischer D; Moncelet AS; Maddens S
    PLoS One; 2019; 14(8):e0221317. PubMed ID: 31465445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.